Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Rama Kongara

Psychiatry Baton Rouge, LA Medical Doctor

NPI 1881867448 CMS profile 267431

5425 Brittany Dr, Baton Rouge, LA 70808

Open in the dashboard

General payments

$2,948

206 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Rama Kongara of Baton Rouge, LA is reported in the CMS Open Payments database as having received $2,948 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $70 3
2021 General $934 60
2020 General $588 35
2019 General $1,356 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rama Kongara
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rama Kongara were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rama Kongara Psychiatry median Middle half National median
2019 $1,356 $184 $59–$605 $163
2020 $588 $119 $36–$372 $114
2021 $934 $143 $43–$576 $132
2022 $70 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sunovion Pharmaceuticals Inc. $713 48 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $670 54 payments
  3. Lundbeck LLC $219 15 payments
  4. Otsuka America Pharmaceutical, Inc. $209 12 payments
  5. Neurocrine Biosciences, Inc. $185 9 payments
  6. ITI, Inc. $182 14 payments
  7. Shire North American Group Inc $171 17 payments
  8. Bausch Health US, LLC $84 4 payments
  9. Teva Pharmaceuticals USA, Inc. $79 6 payments
  10. Vanda Pharmaceuticals Inc. $77 4 payments
  11. Other $358 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,819 187 payments
  2. Education $129 19 payments
Products named General payments · program years 2019–2022
  1. LATUDA $713 48 payments
  2. VYVANSE $444 35 payments
  3. Trintellix Central Nervous System (CNS) $228 25 payments
  4. CAPLYTA $182 14 payments
  5. REXULTI Psychiatry $180 10 payments
  6. TRINTELLIX Neuroscience $170 11 payments
  7. INGREZZA $117 6 payments
  8. REXULTI Psychiatry $117 9 payments
  9. BRINTELLIX $102 6 payments
  10. APLENZIN $84 4 payments
  11. Other $847 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

23

Median for Psychiatry & Neurology: 100

Drug cost

$606

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluphenazine Hcl Generic 23 $606

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record